Top stories in endocrinology: Linagliptin demonstrates CV, renal safety; no CV safety difference between linagliptin and glimepiride

All of the top stories in endocrinology last week were from the American Diabetes Association Scientific Sessions and included results from two trials, one which suggested linagliptin did not increase risk for a new CV event or progression of renal disease when compared with placebo and one which found no differences for incidence of nonfatal myocardial infarction, infarction, nonfatal stroke or cardiovascular death in patients with type 2 diabetes taking either glimepiride or linagliptin.

Other highlights included a study that demonstrated dulaglutide reduced CV and renal risk in type 2 diabetes, two trials that suggested oral semaglutide was superior to empagliflozin and noninferior to liraglutide for lowering HbA1c and a study that found teplizumab temporarily protected against type 1 diabetes in high-risk individuals.

CARMELINA: New linagliptin analyses demonstrate CV, kidney safety across all age, renal impairment groups

SAN FRANCISCO — In adults with type 2 diabetes, established cardiovascular disease and renal impairment, the DPP-IV inhibitor linagliptin did not increase risk for a new CV event or progression of renal disease when compared with placebo, regardless of age or the level of renal impairment, according to new findings from the CARMELINA trial presented at the American Diabetes Association Scientific Sessions. Read more.

CAROLINA: Active-comparator study ‘vindicates’ glimepiride for CV safety

SAN FRANCISCO — A head-to-head comparison of the sulfonylurea glimepiride against the DPP-IV inhibitor linagliptin in a cohort of more than 6,000 adults with type 2 diabetes demonstrated no between-group differences for incidence of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death during a median of 6 years, according to data from the CAROLINA trial.

REWIND: Dulaglutide reduces CV, renal risk in broad type 2 diabetes population

SAN FRANCISCO — In a large cohort of adults with type 2 diabetes with and without established cardiovascular disease, the once-weekly GLP-1 receptor agonist dulaglutide reduced the risk for nonfatal myocardial infarction, nonfatal stroke and CV death by 12% compared with placebo, a speaker said. Read more.

PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c

SAN FRANCISCO — Favorable results from two PIONEER trials of an oral version of the GLP-1 receptor agonist semaglutide were presented at the American Diabetes Association Scientific Sessions. Read more.

Teplizumab temporarily protects against type 1 diabetes in high-risk individuals

SAN FRANCISCO — Those who are most likely to develop type 1 diabetes may be able to stave off the disease for up to 2 years with 2 weeks of treatment with the anti-CD3 antibody teplizumab, according to a speaker. Read more.